北京天坛生物制品股份有限公司2025年半年度报告摘要

Core Viewpoint - The company, Beijing Tiantan Biological Products Co., Ltd., has announced its 2025 semi-annual report, including a profit distribution plan and updates on fundraising and usage of funds [4][9][26]. Group 1: Profit Distribution - The company plans to distribute a cash dividend of 1.5 yuan (including tax) for every 10 shares, totaling 296,605,716.90 yuan (including tax) based on a total share capital of 1,977,371,446 shares as of June 30, 2025 [4][9][24]. - The proposed cash dividend represents 46.89% of the net profit attributable to shareholders for the first half of 2025 [24]. Group 2: Fundraising and Usage - The company raised a total of 3,339,999,994.11 yuan through a non-public offering of shares, with a net amount of 3,330,573,996.69 yuan after deducting issuance costs [26][27]. - As of June 30, 2025, the company has utilized 312,186.38 million yuan of the raised funds, leaving a balance of 31,895.48 million yuan [31]. - The company has not used idle funds for temporary working capital or invested in related products during the reporting period [33][34]. Group 3: Corporate Governance and Risk Assessment - The board of directors has approved a risk assessment report regarding the financial company of China National Pharmaceutical Group, confirming no significant risk management deficiencies [14]. - The company has received commitments from its controlling shareholders to avoid any new competition with its business following a recent acquisition by a related entity [42][44].